{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:06:59Z","timestamp":1785146819744,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"DOI":"10.7759\/cureus.113439","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:34:27Z","timestamp":1785144867000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Imatinib and Nilotinib in Chronic Myeloid Leukemia: A Single-Center Study From Southern Morocco"],"prefix":"10.7759","author":[{"given":"Mossaab","family":"El Mousadik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houda","family":"El Khayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"El Hizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumaima","family":"Bounar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Halloumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rida","family":"Fatima Ezzahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Chakri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afaf","family":"Bouqoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Lahlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022, 36:1703-19. 10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, et al.. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017, 376:917-27. 10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti L","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, et al.. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015, 29:1123-32. 10.1038\/leu.2015.36","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance","volume":"13","author":"Alves R","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance. Cancers (Basel). 2021, 13:4820. 10.3390\/cancers13194820","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley JF","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NC, et al.. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025, 39:1797-813. 10.1038\/s41375-025-02664-w","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2020.05.013","article-title":"Imatinib in the treatment of chronic myeloid leukemia in Morocco (Article in French)","volume":"107","author":"Dakkoune M","year":"2020","unstructured":"Dakkoune M, Qachouh M, Zoukal S, et al.. Imatinib in the treatment of chronic myeloid leukemia in Morocco (Article in French). Bull Cancer. 2020, 107:861-6. 10.1016\/j.bulcan.2020.05.013","journal-title":"Bull Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05747-3","article-title":"Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco","volume":"103","author":"Benchikh S","year":"2024","unstructured":"Benchikh S, Charl\u00e8ne SS, Bousfiha A, et al.. Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco. Ann Hematol. 2024, 103:2765-74. 10.1007\/s00277-024-05747-3","journal-title":"Ann Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000334716","article-title":"International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India","volume":"127","author":"Balasubramanian P","year":"2012","unstructured":"Balasubramanian P, Chendamarai E, Markose P, et al.. International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India. Acta Haematol. 2012, 127:135-42. 10.1159\/000334716","journal-title":"Acta Haematol"},{"key":"ref9","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2017). (2026). Accessed. July 1, 2026: https:\/\/www.ctc.ucl.ac.uk\/TrialDocuments\/Uploaded\/Common%20Terminology%20Criteria%20for%20Adverse%20Events%20(CTCAE)%...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia","volume":"63","author":"Sokal JE","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, et al.. Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia. Blood. 1984, 63:789-99. 10.1182\/blood.V63.4.789.789","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94 Suppl 2","author":"H\u00f6glund M","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015, 94 Suppl 2:S241-7. 10.1007\/s00277-015-2314-2","journal-title":"Ann Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010629","article-title":"High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial","volume":"94","author":"Guilhot F","year":"2009","unstructured":"Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009, 94:1669-75. 10.3324\/haematol.2009.010629","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian HM","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, et al.. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021, 35:440-53. 10.1038\/s41375-020-01111-2","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2478344","article-title":"Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia","volume":"30","author":"Toptas T","year":"2025","unstructured":"Toptas T, Demirtas D, Yanik AM, et al.. Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia. Hematology. 2025, 30:2478344. 10.1080\/16078454.2025.2478344","journal-title":"Hematology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26836","article-title":"Chronic myeloid leukemia without major molecular response after 2\u2009years of treatment with tyrosine kinase inhibitor","volume":"98","author":"Bidikian A","year":"2023","unstructured":"Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic myeloid leukemia without major molecular response after 2\u2009years of treatment with tyrosine kinase inhibitor. Am J Hematol. 2023, 98:639-44. 10.1002\/ajh.26836","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02028-2","article-title":"Survival with chronic myeloid leukaemia after failing milestones","volume":"37","author":"Lauseker M","year":"2023","unstructured":"Lauseker M, Hehlmann R, Hochhaus A, Sau\u00dfele S. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023, 37:2231-6. 10.1038\/s41375-023-02028-2","journal-title":"Leukemia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/506068-effectiveness-and-safety-of-imatinib-and-nilotinib-in-chronic-myeloid-leukemia-a-single-center-study-from-southern-morocco","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:34:28Z","timestamp":1785144868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/506068-effectiveness-and-safety-of-imatinib-and-nilotinib-in-chronic-myeloid-leukemia-a-single-center-study-from-southern-morocco"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.113439","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}